| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Section of Radiodiagnosis and Therapy, Division of Hematology/Oncology, University of California Davis Medical Center, Sacramento, California
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York
Correspondence: For correspondence or reprints contact: Sui Shen, PhD, Radiodiagnosis and Therapy, University of California Davis Medical Center, 1508 Alhambra Blvd., Sacramento, CA 95816.
ABSTRACT
Accurate determination of red marrow radiation is important because myelotoxicity is often dose limiting in radioimmunotherapy. The S-value methodology assumes a fixed red marrow mass as defined by the standard Medical Internal Radiation Dose (MIRD) mathematic phantom. Substantial error can be introduced in marrow radiation estimates because red marrow mass varies from patient to patient. In this work we describe a patient-specific marrow dosimetry methodology that does not require an explicit estimate of marrow mass. Methods: Photon radiation to marrow from all sources can be considered as the total body to marrow. Based on photon radiation from body and electron radiation from blood, a patient-specific marrow dose can be determined by counting blood and total body radioactivity and measuring body weight. Results:The deviation in marrow dose calculation using total body to represent all photon radiation was 3.9% in 66 patients administered 131I-labeled antibodies and was 9.1% in 18 patients administered 67Cu-labeled antibodies. The differences between this patient-specific approach and estimates based on standard anatomy were considerable, ranging from -35% to 88%. The differences were greater when patients' weights differed substantially from the MIRD reference man phantom. Conclusion: For radiopharmaceuticals that do not bind marrow, patient-specific marrow dosimetry can be independent of the actual marrow mass of a patient. Patient-specific marrow dosimetry can be determined using radioactivity concentration in blood and body.
Key Words: marrow dosimetry • radiation dosimetry • radioimmunotherapy • radionuclide therapy
This article has been cited by other articles:
|
|
 |
|
  J. A. Siegel and M. G. Stabin Mass Scaling of S Values for Blood-Based Estimation of Red Marrow Absorbed Dose: The Quest for an Appropriate Method J. Nucl. Med., February 1, 2007; 48(2): 253 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Mamelak, S. Rosenfeld, R. Bucholz, A. Raubitschek, L. B. Nabors, J. B. Fiveash, S. Shen, M.B. Khazaeli, D. Colcher, A. Liu, et al. Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma J. Clin. Oncol., August 1, 2006; 24(22): 3644 - 3650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Siegel, R. B. Sparks, R. M. Sharkey, B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, R. F. Meredith, G. Sgouros, and M. G. Stabin Blood-Based Red Marrow Dosimetry: Where's the Beef? J. Nucl. Med., August 1, 2005; 46(8): 1404 - 1406. [Full Text] [PDF]
|
|
|
|
|
|
R. Schnell, M. Dietlein, J. O. Staak, P. Borchmann, K. Schomaecker, T. Fischer, W. Eschner, H. Hansen, F. Morschhauser, H. Schicha, et al. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody J. Clin. Oncol., July 20, 2005; 23(21): 4669 - 4678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chong, F. T. Lee, W. Hopkins, N. Tebbutt, J. S. Cebon, A. J. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, P. U, et al. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4818 - 4826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shen, A. Forero, A. F. LoBuglio, H. Breitz, M.B. Khazaeli, D. R. Fisher, W. Wang, and R. F. Meredith Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies J. Nucl. Med., April 1, 2005; 46(4): 642 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, G. L. DeNardo, R. F. Meredith, M. G. Stabin, and G. Sgouros Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison J. Nucl. Med., October 1, 2004; 45(10): 1725 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Postema, P. K.E. Borjesson, W. C.A.M. Buijs, J. C. Roos, H. A.M. Marres, O. C. Boerman, R. de Bree, M. Lang, G. Munzert, G. A.M.S. van Dongen, et al. Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer J. Nucl. Med., October 1, 2003; 44(10): 1690 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. DeNardo, G. L. DeNardo, A. Yuan, C. M. Richman, R. T. O'Donnell, P. N. Lara, D. L. Kukis, A. Natarajan, K. R. Lamborn, F. Jacobs, et al. Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT Clin. Cancer Res., September 1, 2003; 9(10): 3938S - 3944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. E. Borjesson, E. J. Postema, J. C. Roos, D. R. Colnot, H. A. M. Marres, M. H. van Schie, G. Stehle, R. de Bree, G. B. Snow, W. J. G. Oyen, et al. Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2003; 9(10): 3961S - 3972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Postema, J. M. M. Raemaekers, W. J. G. Oyen, O. C. Boerman, C. M. P. W. Mandigers, D. M. Goldenberg, G. A. M. S. van Dongen, and F. H. M. Corstens Final Results of a Phase I Radioimmunotherapy Trial Using 186Re-Epratuzumab for the Treatment of Patients with Non-Hodgkin's Lymphoma Clin. Cancer Res., September 1, 2003; 9(10): 3995S - 4002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Colnot, G. J. Ossenkoppele, J. C. Roos, J. J. Quak, R. de Bree, P. K. Borjesson, P. C. Huijgens, G. B. Snow, and G. A. M. S. van Dongen Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study Clin. Cancer Res., November 1, 2002; 8(11): 3401 - 3406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shen, R. F. Meredith, J. Duan, D. J. Macey, M.B. Khazaeli, F. Robert, and A. F. LoBuglio Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy J. Nucl. Med., September 1, 2002; 43(9): 1245 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Colnot, A. J. Wilhelm, J. Cloos, J. C. Roos, R. de Bree, J. J. Quak, G. B. Snow, and G. A.M.S. van Dongen Evaluation of Limited Blood Sampling in a Preceding 99mTc-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of 186Re-cMAb U36 Radioimmunotherapy J. Nucl. Med., September 1, 2001; 42(9): 1364 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kemerink, I. H. Liem, L. Hofstra, H. H. Boersma, W. C.A.M. Buijs, C. P.M. Reutelingsperger, and G. A.K. Heidendal Patient Dosimetry of Intravenously Administered 99mTc-Annexin V J. Nucl. Med., February 1, 2001; 42(2): 382 - 387. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Colnot, J. J. Quak, J. C. Roos, A. van Lingen, A. J. Wilhelm, G. J. van Kamp, P. C. Huijgens, G. B. Snow, and G. A.M.S. van Dongen Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck J. Nucl. Med., December 1, 2000; 41(12): 1999 - 2010. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
